Will BioAge's BGE-102 show a positive Phase 2 proof-of-concept on hsCRP and inflammatory endpoints by end of 2027?
Chance it happens
60%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
BioAge reports a met Phase 2 proof-of-concept on its stated inflammatory or cardio-risk endpoints. Resolution horizon: 2027-12-31. Source: BioAge, registry.
Description
BioAge Labs (Nasdaq: BIOA) is a clinical-stage biotech that uses human aging data to find drug targets. BGE-102 is its oral, once-a-day NLRP3 inhibitor. NLRP3 is an inflammasome — a molecular alarm inside immune cells that, when it stays switched on with age, drives the chronic low-grade inflammation now thought to accelerate heart disease, metabolic decline, and other age-related conditions. BGE-102 is a small molecule designed to dial that alarm down; because it is brain-penetrant it can also reach inflammation inside the central nervous system. The readout everyone watches is hsCRP (high-sensitivity C-reactive protein), a standard blood marker of inflammation — the lower it goes, the more the drug is quieting the inflammatory signal. In Phase 1, BGE-102 produced what BioAge called potential best-in-class hsCRP reductions with once-daily oral dosing. The Phase 2 proof-of-concept trial this question is about is QUELL-CV. It is randomized, double-blind, placebo-controlled and dose-ranging: roughly 160 adults who have obesity, elevated inflammation (hsCRP above 3 mg/L) and at least one further cardiovascular risk factor are split across four groups — placebo, or BGE-102 at 30, 60, or 90 mg once daily — and treated for 12 weeks. The primary endpoint is the percent change in hsCRP from the start of dosing. The first participant was dosed in June 2026, and BioAge expects topline data in the second half of 2026. Trial registry record: https://clinicaltrials.gov/study/NCT07656727 BioAge is also expanding BGE-102 into a second indication: a Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME — fluid build-up in the retina that blurs vision in people with diabetes), planned to start in mid-2026 with results anticipated in mid-2027; that is the DME data referenced in one of the answer options. In plain words, this market asks whether BGE-102 will hit a positive Phase 2 proof-of-concept on its inflammatory / cardiovascular-risk endpoints — chiefly the hsCRP reduction in QUELL-CV — by the end of 2027, and if so, when. Resolution horizon: 2027-12-31.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a BioAge press release announcing initiation of QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 in elevated cardiovascular-risk patients. It is directly relevant because it confirms the trial exists, its proof-of-concept framing, and the inflammatory/cardio-risk context tied to eventual resolution by end of 2027.
This is a BioAge press release reporting Phase 1 data for BGE-102, including hsCRP reductions and plans/positioning around inflammatory and cardio-risk endpoints. It is directly relevant because it establishes the program, mechanism, and early biomarker signal that bear on the likelihood of a positive Phase 2 proof-of-concept by the end of 2027.
This is a news report about BioAge's positive Phase 1 data for BGE-102. It is relevant because early human safety/pharmacodynamic results and any stated development plans inform the likelihood of achieving a positive Phase 2 proof-of-concept by the end of 2027, though it is not itself a Phase 2 result.
This is a news report that BioAge has dosed the first participant in the Phase 2 QUELL-CV trial of BGE-102 in adults with obesity at elevated cardiovascular risk. It is relevant because trial initiation affects the likelihood and timing of whether BioAge can generate Phase 2 proof-of-concept data on hsCRP and related inflammatory/cardio-risk endpoints by the end of 2027.
This appears to be a trade-news report describing Phase 1 data for BioAge's BGE-102, including a large hsCRP reduction. It is relevant because early anti-inflammatory biomarker activity on hsCRP bears directly on the likelihood of later Phase 2 proof-of-concept success on inflammatory or cardio-risk endpoints by 2027.
This appears to be a BioAge Labs LinkedIn post reporting positive Phase 1 data for BGE-102, an NLRP3 inhibitor. It is relevant because early clinical safety/pharmacology signals for the same asset bear on the likelihood of later Phase 2 proof-of-concept success on inflammatory endpoints, though it is not itself Phase 2 evidence.
This appears to be a social/news-style post stating that BioAge Labs initiated the QUELL-CV Phase 2 trial for BGE-102, which is relevant because trial initiation is a prerequisite milestone toward any Phase 2 proof-of-concept readout by the end of 2027. It does not report efficacy results, but it is on-topic evidence about program status and timeline.